About the Company
AgeX Therapeutics, Inc. iis focused on developing and commercializing innovative therapeutics for human aging. Its PureStem® and UniverCyte™ manufacturing and immunotolerance technologies are designed to work together to generate highly-defined, universal, allogeneic, off-the-shelf pluripotent stem cell-derived young cells of any type for application in a variety of diseases with a high unmet medical need. AgeX has two preclinical cell therapy programs: AGEX-VASC1 (vascular progenitor cells) for tissue ischemia and AGEX-BAT1 (brown fat cells) for Type II diabetes. AgeX's revolutionary longevity platform induced Tissue Regeneration (iTR™) aims to unlock cellular immortality and regenerative capacity to reverse age-related changes within tissues. AgeX is developing its core product pipeline for use in the clinic to extend human healthspan and is seeking opportunities to establish licensing and collaboration agreements around its broad IP estate and proprietary technology platforms.
Sector
Professional, Scientific, and Technical Services
Industry
Research and Development in Biotechnology
Employees
9
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $AGE News
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
ALAMEDA, Calif.--(BUSINESS WIRE)-- AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that ...
Longevity and Anti-senescence Therapy Market 2023 Expected to Reach Significant Rate by 2028
Longevity and Anti-senescence Therapy Market Report offers an Complete view about Longevity and Anti-senescence ...
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
AgeX Therapeutics, Inc. (“AgeX”: NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received ...
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
ALAMEDA, Calif., November 25, 2022--(BUSINESS WIRE)--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human ...
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
AgeX Therapeutics, Inc. AGE, a biotechnology company developing therapeutics for human aging and regeneration, announced today that on November 22, 2022 it received notification from the staff of ...
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
ALAMEDA, Calif., November 25, 2022--(BUSINESS WIRE)--AgeX Therapeutics, Inc. ("AgeX": NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced ...
Loading the latest forecasts...